Computational Drug Repurposing for All EBS Cases

Launched by JOYCE TENG · Aug 30, 2017

Keywords

ClinConnect Summary

This clinical trial is studying a skin condition called Epidermolysis Bullosa (EB), which causes the skin to be very fragile and easily blistered. The researchers want to learn how the skin behaves differently in people with EB, especially between areas of skin that have blisters and those that do not. They will be using advanced computer techniques to find existing medications that could help improve wound healing and reduce pain for all types of EB. The exciting part is that the medications they are looking at have already been approved for other uses, which means they could be repurposed for EB patients more quickly and affordably than developing new drugs from scratch.

Anyone of any age diagnosed with EB or healthy individuals without EB can participate in the study, as long as they can attend study visits for tissue and blood sample collection. However, people who are pregnant, breastfeeding, or have serious health issues that could affect their safety or the study will not be included. Participants can expect to contribute to important research that may lead to better treatments and an improved quality of life for those suffering from this condition.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Subjects of all ages
• • Diagnosis of all subtypes of EB subjects
• • Healthy, non-EB subjects
• • Ability to complete study visit to collect tissue and blood specimen
• Exclusion Criteria:
• • Pregnancy, breast feeding
• • Prior history of liver disease
• • Serious known concurrent medical illness or infection, which could potentially present a safety risk and/or prevent tissue collection from subjects